Navigation Links
In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression

sion (MADRS <12) by the end of the study, compared with 29 percent of placebo-treated patients (p< 0.0001).
Compared with placebo, duloxetine-treated patients also experienced a significantly better outcome in response to pain (>30% reduction from baseline in average pain severity) and improved daily functioning not limited by pain (BPI interference subscale).
10.5 percent of study patients treated with duloxetine and 5.5 percent of patients treated with placebo discontinued treatment because of adverse events. The most commonly reported adverse events among those taking duloxetine were nausea (24.7 percent for duloxetine-treated patients, vs. 7.9 percent for those taking placebo), excessive sweating (11.7 percent vs. 2.4 percent), dry mouth (10.5 percent vs. 3.6 percent), headache (7.4 percent vs. 9.1 percent), fatigue (8.0 percent vs. 1.8 percent), dizziness (5.6 percent vs. 3.6 percent), and constipation (5.6 percent vs. 1.2 percent).
Notes to Editors:

Methodology

This double-blind, eight week study included 327 patients randomized to placebo (n=165) or duloxetine 60mg (n=162) and was conducted in Belgium, Finland, France, Germany and Slovakia.
Trial participants were outpatients aged 18 or older presenting with:
Major depressive disorder (MDD), as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS, with a score of >20) and the Clinical Global Impression of Severity scale (CGI-S, with a score of >4).
At least moderate pain not attributable to a diagnosed pain syndrome, as assessed by the Brief Pain Inventory (BPI, with a score of >3), a validated scale used to assess the severity of pain and the impact of pain on daily functions.
The primary outcome measure was the brief pain inventory average pain score at endpoint, and the change from baseline, using the mixed-model-repeated-measures (MMRM) method.
Secondary measures included MADRS total score, CGI-S, SCL-90-R, response and remission, s
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, in Reducing Painful Symptoms in Ssri Non- or Partial-responders with Depression
2. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
Post Your Comments:
(Date:8/26/2014)... Aug. 26, 2014 Research and ... "Global Veterinary Diagnostics Market 2014-2018" report ... include various tests, which are used to detect ... and biomedical researchers are mainly availing these diagnostic ... Acid/Ribonucleic Acid testing), immunodiagnostics, clinical chemistry, and hematology. ...
(Date:8/26/2014)... 2014 Using publicly released 2015 rate filings ... for five common specialty drugs. Specialty drugs have ... high costs and shortage of generic alternatives. They ... prescription, and are used for a broad variety ... HealthPocket found that among 2015 ...
(Date:8/26/2014)... , Aug. 26, 2014  Sorrento Therapeutics, ... late-stage clinical oncology company developing new treatments for ... it has received funding to advance an immunotherapy ... treatment of IPF, which affects more than 100,000 ... lungs increases and patients gradually lose the ability ...
Breaking Medicine Technology:Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis 2Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis 32015 Platinum Plans Are Best Buy for Consumers Using Expensive Specialty Drugs 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 3
... Maine, July 14, 2011 IDEXX Laboratories, Inc. (Nasdaq: ... its 2011 second quarter financial results for Friday, July ... conduct an analyst conference call beginning at 9:00 a.m. ... Individuals can access a live Webcast of the ...
... Biomedical Corporation (OTCBB:QTXB), an emerging leader in the ... on its patented technology platforms for the worldwide ... the lawsuit with NURX, its prior Joint Venture ... operations to expand its over-the-counter products and laboratory ...
Cached Medicine Technology:QuantRx Biomedical Settles Suit: Launches New PAD-Based Genomic Diagnostic Products 2QuantRx Biomedical Settles Suit: Launches New PAD-Based Genomic Diagnostic Products 3
(Date:8/27/2014)... Ellen V. Krieger, DDS released a new ... video is meant to describe the business and industry best ... over 28 years of cosmetic and family dentistry experience, Dr ... patients feel welcomed and cared for. , Dr. Krieger has ... years, building a solid reputation of offering bright, friendly service ...
(Date:8/27/2014)... Los Angeles, CA (PRWEB) August 27, 2014 ... Media Meetup event in collaboration with Diabetes Community Advocacy ... on October 24-25, 2014 at Embassy Suites LAX ... “DiabetesSisters’ Social Media Meetup featuring DSMA Live”, an event ... on Friday evening, October 24th. , Interactive in many ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 ... management, governance, and compliance software solutions for next-generation ... made Inc. magazine’s Inc. 500|5000, an exclusive ranking ... fifth consecutive year. AvePoint joins brands such as ... the 2014 edition. , This underscores continued ...
(Date:8/27/2014)... one of the most loved online bamboo product suppliers; the ... Recently, it has announced its new selection of bamboo ... to offer one-stop shopping solutions for people who want to ... is providing big discounts for all the brand new bamboo ... discounted price (up to 30% off) before the deadline on ...
(Date:8/27/2014)... CA (PRWEB) August 27, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... announced on August 1, that Organic Raw Carob Powder ... is recalled due to possible contamination with ... people with weakened immune systems. In healthy people it ...
Breaking Medicine News(10 mins):Health News:Ellen V. Krieger, DDS of McLean, Virginia Announces New Video Describing Industry Best Practices 2Health News:DiabetesSisters and Diabetes Community Advocacy Foundation Join Forces to Bring Together People with Diabetes in Los Angeles 2Health News:DiabetesSisters and Diabetes Community Advocacy Foundation Join Forces to Bring Together People with Diabetes in Los Angeles 3Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 2Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 3Health News:Brand New Bamboo Plywoods Now Offered At BambooIndustry.com 2Health News:Organic Raw Carob Powder by Sunburst SuperFoods Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... Daiichi Sankyo, Inc. and Eli Lilly and ... the U.S. Food and Drug Administration (FDA) approved Effient(TM) ... (including stent thrombosis) in patients with acute coronary syndromes ... percutaneous coronary intervention (PCI). PCI usually includes the ...
... tip the scales toward more health risks, researcher says , FRIDAY, ... night, make you snap at your spouse and children, and make ... can also make you gain weight -- especially if you,re overweight ... people out, and stress has been linked to a number of ...
... a bi-national team of global health researchers at the University ... among male clients of female sex workers in Tijuana, has ... unprotected sex. They also reported a high prevalence of ... is necessary to prevent the spread of HIV and other ...
... ecological study of its kind in the world, a Wake ... finding that groundwater and airborne manganese in North Carolina correlates ... ... County in North Carolina: An Ecological Study," was published online ...
... July 10 Compirion Healthcare Solutions, a whole-hospital process improvement ... to help educate hospital executives, managers and clinicians in strategies for ... be found at www.compirion.com/webinars along with times, ... entitled Achieving Early AM Hospital Discharges: ...
... , WASHINGTON, July 10 The Department of Veterans ... design and build a free-standing spinal cord injury center ... The contract was awarded to the C3T Construction Company ... building will have a connecting tunnel, providing access to ...
Cached Medicine News:Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 2Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 3Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 4Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 5Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 6Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 7Health News:Job Stress, Economy Weighing on Americans 2Health News:Risky sexual behavior among male clients of Tijuana sex workers heightens risk of HIV transmission 2Health News:Environmental manganese good in trace amounts but can correlate to cancer rates 2Health News:Compirion Healthcare Sponsors Free Webinar On Achieving Early Hospital Discharges 2Health News:Compirion Healthcare Sponsors Free Webinar On Achieving Early Hospital Discharges 3
... Bio-Modular total shoulder system is ... use in both hemiarthroplasty and ... Modularity in combination with a ... component options provide the surgeon ...
...
...
... Knee employs titanium alloy plasma spray ... fixation surface. Biomet's ArCom processed polyethylene ... proven bearing material. The Maxim Knee ... Modular tibial components offer excellent sizing ...
Medicine Products: